Pharmacogenetic profiling in the treatment of heart disease

Translational Research

Volumn 154, Issue 6, 2009, Pages 295-302

  Dorn II, Gerald W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CYTOCHROME P450 2D6; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; G PROTEIN COUPLED RECEPTOR KINASE; METOPROLOL; PROPRANOLOL;

ANGINA PECTORIS; CHRONOTROPISM; CLINICAL TRIAL; DNA FINGERPRINTING; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INOTROPISM; LOSS OF FUNCTION MUTATION; MORTALITY; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 70449487347     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.07.010     Document Type: Review

References (43)

1. Dorn G.W., and Cresci S. The mechanistic imperative for pharmacogenomics. Pharmacogenomics 9 (2008) 801-803
2. Roden D.M., and Stein C.M. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 119 (2009) 2127-2130
3. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
4. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
5. Fauchier L., Pierre B., de Labriolle A., and Babuty D. Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: a meta-analysis of randomised controlled trials. Eur J Heart Fail 9 (2007) 1136-1139
6. Mason D.A., Moore J.D., Green S.A., and Liggett S.B. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274 (1999) 12670-12674
7. Liggett S.B., Cresci S., Kelly R.J., et al. A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure. Nat Med 14 (2008) 510-517
8. Sachse C., Brockmoller J., Bauer S., and Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60 (1997) 284-295
9. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103 (2006) 11288-11293
10. Pacanowski M.A., Zineh I., Li H., et al. Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. J Trans Med 6 (2008) 11
11. Cresci S, Kelly RJ, Cappola TP, et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol. In press.
12. Joseph S.S., Lynham J.A., Grace A.A., Colledge W.H., and Kaumann A.J. Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors. Br J Pharmacol 142 (2004) 51-56
13. 2-adrenergic receptor signaling. J Biol Chem 278 (2003) 10784-10789
14. 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9 (2003) 1300-1305
15. Bruck H., Leineweber K., Temme T., et al. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol 46 (2005) 2111-2115
16. Molenaar P., Chen L., Semmler A.B., Parsonage W.A., and Kaumann A.J. Human heart beta-adrenoceptors: beta1-adrenoceptor diversification through 'affinity states' and polymorphism. Clin Exp Pharmacol Physiol 34 (2007) 1020-1028
17. Terra S.G., Pauly D.F., Lee C.R., et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 77 (2005) 127-137
18. Rochais F., Vilardaga J.P., Nikolaev V.O., Bunemann M., Lohse M.J., and Engelhardt S. Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 117 (2007) 229-235
19. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., et al. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and b-blocker response in human heart failure. Proc Natl Acad Sci U S A 103 (2006) 11288-11293
20. BEST Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001) 1659-1667
21. Kaye D.M., Smirk B., Finch S., Williams C., and Esler M.D. Interaction between cardiac sympathetic drive and heart rate in heart failure: modulation by adrenergic receptor genotype. J Am Coll Cardiol 44 (2004) 2008-2015
22. Kunapuli P., and Benovic J.L. Cloning and expression of GRK5: a member of the G protein-coupled receptor kinase family. Proc Natl Acad Sci U S A 90 (1993) 5588-5592
23. Premont R.T., Koch W.J., Inglese J., and Lefkowitz R.J. Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases. J Biol Chem 269 (1994) 6832-6841
24. Wang W.C., Mihlbachler K.A., Bleecker E.R., Weiss S.T., and Liggett S.B. A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2-adrenergic receptors. Pharmacogenet Genom 18 (2008) 729-732
25. Lennard M.S., Silas J.H., Freestone S., Ramsay L.E., Tucker G.T., and Woods H.F. Oxidation phenotype-a major determinant of metoprolol metabolism and response. N Engl J Med 307 (1982) 1558-1560
26. Regardh C.G., and Johnsson G. Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet 5 (1980) 557-569
27. Kirchheiner J. CYP2D6 phenotype prediction from genotype: which system is the best?. Clin Pharmacol Ther 83 (2008) 225-227
28. Chou W.H., Yan F.X., Robbins-Weilert D.K., et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 49 (2003) 542-551
29. Raimundo S., Fischer J., Eichelbaum M., Griese E.U., Schwab M., and Zanger U.M. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10 (2000) 577-581
30. Zanger U.M., Fischer J., Raimundo S., et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11 (2001) 573-585
31. Fux R., Morike K., Prohmer A.M., et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78 (2005) 378-387
32. Rau T., Heide R., Bergmann K., et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12 (2002) 465-472
33. Sharp C.F., Gardiner S.J., Jensen B.P., et al. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. Pharmacogenom J 9 (2009) 175-184
34. Rau T., Wuttke H., Michels L.M., et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 85 (2009) 269-272
35. Bijl M.J., Visser L.E., van Schaik R.H., et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther 85 (2009) 45-50
36. Goryachkina K., Burbello A., Boldueva S., Babak S., Bergman U., and Bertilsson L. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol 64 (2008) 1163-1173
37. Wuttke H., Rau T., Heide R., et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72 (2002) 429-437
38. Zineh I., Beitelshees A.L., Gaedigk A., et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76 (2004) 536-544
39. Brockmoller J., Kirchheiner J., Schmider J., et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 72 (2002) 438-452
40. Murphy Jr. G.M., Kremer C., Rodrigues H.E., and Schatzberg A.F. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160 (2003) 1830-1835
41. Wedlund P.J., and de L.J. Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence?. Clin Pharmacol Ther 75 (2004) 373-375
42. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38 (2001) 2101-2113
43. Brophy J.M., Joseph L., and Rouleau J.L. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 134 (2001) 550-560